These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 8250861)

  • 1. Natural autoantibodies cross-react with a peptide derived from the second conserved region of HIV-1 envelope glycoprotein gp120.
    Veliković V; Metlas R; Danilo V; Cavor L; Pejinović N; Dujuć A; Zakhariev S; Guarnaccia C; Pongor S
    Biochem Biophys Res Commun; 1993 Nov; 196(3):1019-24. PubMed ID: 8250861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spectral and sequence similarity between vasoactive intestinal peptide and the second conserved region of human immunodeficiency virus type 1 envelope glycoprotein (gp120): possible consequences on prevention and therapy of AIDS.
    Veljkovic V; Metlas R; Raspopovic J; Pongor S
    Biochem Biophys Res Commun; 1992 Dec; 189(2):705-10. PubMed ID: 1472041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural autoantibodies in healthy neonatals recognizing a peptide derived from the second conserved region of HIV-1 gp120.
    Vujicić AD; Gemović B; Veljković V; Glisić S; Veljković N
    Vojnosanit Pregl; 2014 Apr; 71(4):352-61. PubMed ID: 24783415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of peptide mimetics of HIV-1 gp120 for prevention and therapy of HIV disease.
    Veljkovic N; Branch DR; Metlas R; Prljic J; Vlahovicek K; Pongor S; Veljkovic V
    J Pept Res; 2003 Oct; 62(4):158-66. PubMed ID: 12969195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding of glycoprotein 120 and peptides from the HIV-1 envelope by autoantibodies in mice with experimentally induced systemic lupus erythematosus and in patients with the disease.
    Bermas BL; Petri M; Berzofsky JA; Waisman A; Shearer GM; Mozes E
    AIDS Res Hum Retroviruses; 1994 Sep; 10(9):1071-7. PubMed ID: 7826694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conformational preferences of a chimeric peptide HIV-1 immunogen from the C4-V3 domains of gp120 envelope protein of HIV-1 CAN0A based on solution NMR: comparison to a related immunogenic peptide from HIV-1 RF.
    Vu HM; de Lorimier R; Moody MA; Haynes BF; Spicer LD
    Biochemistry; 1996 Apr; 35(16):5158-65. PubMed ID: 8611499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptides mimicking selected disulfide loops in HIV-1 gp120, other than V3, do not elicit virus-neutralizing antibodies.
    Neurath AR; Strick N; Fields R; Jiang S
    AIDS Res Hum Retroviruses; 1991 Aug; 7(8):657-62. PubMed ID: 1718344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
    Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
    J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The conserved carboxy terminal region of HIV-1 gp120 is recognized by seronegative HIV-exposed people.
    Brown L; Souberbielle BE; Marriott JB; Westby M; Desselberger U; Kaye T; Gougeon ML; Dalgleish A
    AIDS; 1999 Dec; 13(18):2515-21. PubMed ID: 10630520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The presence of antibodies recognizing a peptide derived from the second conserved region of HIV-1 gp120 correlates with non-progressive HIV infection.
    Djordjevic A; Veljkovic M; Antoni S; Sakarellos-Daitsiotis M; Krikorian D; Zevgiti S; Dietrich U; Veljkovic N; Branch DR
    Curr HIV Res; 2007 Sep; 5(5):443-8. PubMed ID: 17896963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactions of Ugandan antisera with peptides encoded by V3 loop epitopes of human immunodeficiency virus type 1.
    Smith JD; Bruce CB; Featherstone AS; Downing RG; Biryahawaho B; Clegg JC; Carswell JW; Oram JD
    AIDS Res Hum Retroviruses; 1994 May; 10(5):577-83. PubMed ID: 7522494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Synthesis and comparative analysis of antigenic activity of peptides from hypervariable region V3 of human immunodeficiency virus I gp120 surface glycoprotein].
    Semiletov IuA; Rzhaninova AA; Garaev MM
    Bioorg Khim; 1994 Oct; 20(10):1070-9. PubMed ID: 7826406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigenic activity of three chimeric synthetic peptides of the transmembrane (gp41) and the envelope (gp120) glycoproteins of HIV-1 virus.
    Marin MH; Peña LP; Tanty CR; Higginson Clarke D; Arenas MA; Noguerol KR; León CS
    Prep Biochem Biotechnol; 2004 Aug; 34(3):227-37. PubMed ID: 15461139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative studies on neutralisation of primary HIV-1 isolates by human sera and rabbit anti-V3 peptide sera.
    Lawoko AL; Johansson B; Hjalmarsson S; Christensson B; Ljungberg B; Al-Khalili L; Sjölund M; Pipkorn R; Fenyö EM; Blomberg J
    J Med Virol; 1999 Oct; 59(2):169-79. PubMed ID: 10459152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies reactive with C-terminus of the second conserved region of HIV-1gp120 as possible prognostic marker and therapeutic agent for HIV disease.
    Veljkovic N; Branch DR; Metlas R; Prljic J; Manfredi R; Stringer WW; Veljkovic V
    J Clin Virol; 2004 Dec; 31 Suppl 1():S39-44. PubMed ID: 15567092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human immunodeficiency virus type 1 gp120 C5 region mimics the HLA class I alpha 1 peptide-binding domain.
    Lopalco L; De Santis C; Meneveri R; Longhi R; Ginelli E; Grassi F; Siccardi AG; Beretta A
    Eur J Immunol; 1993 Aug; 23(8):2016-21. PubMed ID: 8344367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of VIP/NTM-reactive natural antibodies in therapy of HIV disease.
    Veljkovic V; Metlas R
    Int Rev Immunol; 2004; 23(5-6):437-45. PubMed ID: 15370275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisera raised against the second variable region of the external envelope glycoprotein of human immunodeficiency virus type 1 cross-neutralize and show an increased neutralization index when they act together with antisera to the V3 neutralization epitope.
    Davis D; Stephens DM; Carne CA; Lachmann PJ
    J Gen Virol; 1993 Dec; 74 ( Pt 12)():2609-17. PubMed ID: 7506300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-reactive potential of rabbit antibodies raised against a cyclic peptide representing a chimeric V3 loop of HIV-1 gp120 studied by biosensor technique and ELISA.
    Richalet-Sécordel PM; Deslandres A; Plaué S; You B; Barré-Sinoussi F; Van Regenmortel MH
    FEMS Immunol Med Microbiol; 1994 Jun; 9(1):77-87. PubMed ID: 7920467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.